Pre-made Imdevimab biosimilar ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-267
Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Imdevimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Casirivimab/imdevimab, sold under the brand name REGEN-COV, is an experimental medicine developed by the American biotechnology company Regeneron Pharmaceuticals. It is an artificial "antibody cocktail" designed to produce resistance against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic. It consists of two monoclonal antibodies, casirivimab (REGN10933) and imdevimab (REGN10987) that must be mixed together. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Imdevimab biosimilar,Whole mAb)|
|Target||SARS-CoV-2 Spike RBD|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||6xdg:CA|
|99% SI Structure||None|
|95-98% SI Structure||None|